carnitine has been researched along with Peripheral Arterial Diseases in 8 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "This study investigated the efficacy, safety and tolerability of propionyl-L-carnitine (PLC) in patients with intermittent claudication in the Chinese population." | 9.17 | A study on the efficacy and safety assessment of propionyl-L-carnitine tablets in treatment of intermittent claudication. ( Chen, Z; Jin, B; Li, J; Li, K; Li, L; Liu, C; Luo, T; Yang, B; Zhang, J; Zhang, X; Zheng, Q, 2013) |
| " Propionyl-L-carnitine (PLC) is efficacious in improving pain free walking distance in peripheral arterial disease with claudication; it also exerts favorable effects on the arterial wall and on endothelial function." | 9.16 | Propionyl-L-carnitine improves endothelial function, microcirculation and pain management in critical limb ischemia. ( Arosio, E; De Marchi, S; Fondrieschi, L; Prior, M; Rigoni, A; Rulfo, F; Scuro, A; Zecchetto, S, 2012) |
| "The objective of this review is to determine whether propionyl-L-carnitine is efficacious compared with placebo, other drugs, or other interventions used for treatment of intermittent claudication (e." | 9.12 | Propionyl-L-carnitine for intermittent claudication. ( Campens, L; de Backer, TL; De Bacquer, D; Kamoen, V; Van Bortel, L; Vander Stichele, R, 2021) |
| "Cilostazol and L-carnitine have been used as a first-line drug and supplement, respectively, in patients with peripheral arterial disease with intermittent claudication." | 7.81 | Combination of Cilostazol and L-Carnitine Improves Walking Performance in Peripheral Arterial Disease Model Rats. ( Orito, K; Sahara, H; Shiga, T, 2015) |
| "This study investigated the efficacy, safety and tolerability of propionyl-L-carnitine (PLC) in patients with intermittent claudication in the Chinese population." | 5.17 | A study on the efficacy and safety assessment of propionyl-L-carnitine tablets in treatment of intermittent claudication. ( Chen, Z; Jin, B; Li, J; Li, K; Li, L; Liu, C; Luo, T; Yang, B; Zhang, J; Zhang, X; Zheng, Q, 2013) |
| " Propionyl-L-carnitine (PLC) is efficacious in improving pain free walking distance in peripheral arterial disease with claudication; it also exerts favorable effects on the arterial wall and on endothelial function." | 5.16 | Propionyl-L-carnitine improves endothelial function, microcirculation and pain management in critical limb ischemia. ( Arosio, E; De Marchi, S; Fondrieschi, L; Prior, M; Rigoni, A; Rulfo, F; Scuro, A; Zecchetto, S, 2012) |
| "The objective of this review is to determine whether propionyl-L-carnitine is efficacious compared with placebo, other drugs, or other interventions used for treatment of intermittent claudication (e." | 5.12 | Propionyl-L-carnitine for intermittent claudication. ( Campens, L; de Backer, TL; De Bacquer, D; Kamoen, V; Van Bortel, L; Vander Stichele, R, 2021) |
| "Cilostazol and L-carnitine have been used as a first-line drug and supplement, respectively, in patients with peripheral arterial disease with intermittent claudication." | 3.81 | Combination of Cilostazol and L-Carnitine Improves Walking Performance in Peripheral Arterial Disease Model Rats. ( Orito, K; Sahara, H; Shiga, T, 2015) |
| " Serum markers of endothelial dysfunction and inflammation were unchanged, but short-chain acylcarnitine concentrations were significantly decreased." | 3.79 | Daily non-soy legume consumption reverses vascular impairment due to peripheral artery disease. ( Baldwin, A; Blewett, H; Guzman, RP; O, K; Taylor, CG; Weighell, W; Wright, B; Zahradka, P, 2013) |
| "l-carnitine is an important co-factor in fatty-acid metabolism, and its deficiency is associated with insulin resistance, which is independently associated with arterial stiffness." | 1.51 | Association of Low Serum l-Carnitine Levels with Peripheral Arterial Stiffness in Patients Who Undergo Kidney Transplantation. ( Ho, GJ; Hsu, BG; Lai, YH; Lee, MC; Liu, CH, 2019) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 7 (87.50) | 24.3611 |
| 2020's | 1 (12.50) | 2.80 |
| Authors | Studies |
|---|---|
| Kamoen, V | 1 |
| Vander Stichele, R | 1 |
| Campens, L | 1 |
| De Bacquer, D | 1 |
| Van Bortel, L | 1 |
| de Backer, TL | 1 |
| Lai, YH | 1 |
| Lee, MC | 1 |
| Ho, GJ | 1 |
| Liu, CH | 1 |
| Hsu, BG | 1 |
| Luo, T | 1 |
| Li, J | 1 |
| Li, L | 1 |
| Yang, B | 1 |
| Liu, C | 1 |
| Zheng, Q | 1 |
| Jin, B | 1 |
| Chen, Z | 1 |
| Li, K | 1 |
| Zhang, X | 1 |
| Zhang, J | 1 |
| Zahradka, P | 1 |
| Wright, B | 1 |
| Weighell, W | 1 |
| Blewett, H | 1 |
| Baldwin, A | 1 |
| O, K | 1 |
| Guzman, RP | 1 |
| Taylor, CG | 1 |
| Shiga, T | 1 |
| Sahara, H | 1 |
| Orito, K | 1 |
| Riccioni, C | 1 |
| Sarcinella, R | 1 |
| Izzo, A | 1 |
| Palermo, G | 1 |
| Liguori, M | 1 |
| Caliumi, C | 1 |
| Carloni, E | 1 |
| Paolucci, AM | 1 |
| D'andrea, P | 1 |
| Pompili, S | 1 |
| Goldenberg, NA | 1 |
| Krantz, MJ | 1 |
| Hiatt, WR | 1 |
| De Marchi, S | 1 |
| Zecchetto, S | 1 |
| Rigoni, A | 1 |
| Prior, M | 1 |
| Fondrieschi, L | 1 |
| Scuro, A | 1 |
| Rulfo, F | 1 |
| Arosio, E | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Blinded, Randomized, Controlled Study to Examine the Bioavailability of Compounds From Different Bean Varieties in Healthy Individuals.[NCT02342340] | 8 participants (Actual) | Interventional | 2015-01-31 | Completed | |||
| Evaluation of Cilostazol in Combination With L-Carnitine in Subjects With Intermittent Claudication[NCT00822172] | Phase 4 | 164 participants (Actual) | Interventional | 2008-09-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Subjects were asked to complete a standardized exercise treadmill test using a modified Gardner protocol. Subjects walked on the treadmill until they were physically unable to walk further either as a result of their peripheral artery disease (PAD) symptoms or other non-PAD symptoms. The time during the conduct of the exercise treadmill test at which the subject first reported claudication symptoms is referred to as the claudication onset time (COT) and reported in minutes/seconds. The exercise treadmill test was conducted at Screening, Baseline, Day 90, and Day 180 visits. The log transformation is used to make highly skewed distributions less skewed. (NCT00822172)
Timeframe: Baseline, Day 180
| Intervention | Log Minutes (Mean) |
|---|---|
| Cilostazol + L-Carnitine | 1.065 |
| Cilostazol + Placebo | 0.896 |
Subjects were asked to complete a standardized exercise treadmill test using a modified Gardner protocol. Subjects walked on the treadmill until they were physically unable to walk further either as a result of their peripheral artery disease (PAD) symptoms or other non-PAD symptoms. The time during the conduct of the exercise treadmill test at which the subject first reported claudication symptoms is referred to as the claudication onset time (COT) and reported in minutes/seconds. The exercise treadmill test was conducted at Screening, Baseline, Day 90, and Day 180 visits. The log transformation is used to make highly skewed distributions less skewed. (NCT00822172)
Timeframe: Baseline, Day 90
| Intervention | Log Minutes (Mean) |
|---|---|
| Cilostazol + L-Carnitine | 1.001 |
| Cilostazol + Placebo | 0.815 |
Subjects were asked to complete a standardized exercise treadmill test using a modified Gardner protocol. Subjects walked on the treadmill until they were physically unable to walk further either as a result of their peripheral artery disease (PAD) symptoms or other non-PAD symptoms. This maximum time walked is referred to as the peak walking time (PWT) and reported in minutes/seconds. The exercise treadmill test was conducted at Screening, Baseline, Day 90, and Day 180 visits. The log transformation is used to make highly skewed distributions less skewed. (NCT00822172)
Timeframe: Baseline, Day 180
| Intervention | Log Minutes (Mean) |
|---|---|
| Cilostazol + L-Carnitine | 0.241 |
| Cilostazol + Placebo | 0.134 |
Subjects were asked to complete a standardized exercise treadmill test using a modified Gardner protocol. Subjects walked on the treadmill until they were physically unable to walk further either as a result of their peripheral artery disease (PAD) symptoms or other non-PAD symptoms. This maximum time walked is referred to as the peak walking time (PWT) and reported in minutes/seconds. The exercise treadmill test was conducted at Screening, Baseline, Day 90, and Day 180 visits. The log transformation is used to make highly skewed distributions less skewed. (NCT00822172)
Timeframe: Baseline, Day 180
| Intervention | Log Minutes (Mean) |
|---|---|
| Cilostazol + L-Carnitine | 0.267 |
| Cilostazol + Placebo | 0.145 |
Subjects were asked to complete a standardized exercise treadmill test using a modified Gardner protocol. Subjects walked on the treadmill until they were physically unable to walk further either as a result of their peripheral artery disease (PAD) symptoms or other non-PAD symptoms. This maximum time walked is referred to as the peak walking time (PWT) and reported in minutes/seconds. The exercise treadmill test was conducted at Screening, Baseline, Day 90, and Day 180 visits. The log transformation is used to make highly skewed distributions less skewed. (NCT00822172)
Timeframe: Baseline, Day 90
| Intervention | Log Minutes (Mean) |
|---|---|
| Cilostazol + L-Carnitine | 0.166 |
| Cilostazol + Placebo | 0.139 |
Subjects completed the Walking Impairment Questionnaire (WIQ) whereby they were asked about their maximal walking distance before having to rest as a result of claudication symptoms associated with their peripheral artery disease (PAD). The WIQ was administered at the Baseline, Day 90, and Day 180 visits. On the WIQ subjects were asked a series of questions related to their degree of physical difficulty that best described how hard it was for the subject to walk on level ground without stopping to rest. The questions began by asking the degree of difficulty walking around indoors, then 50 feet, 150 feet, 300 feet, 600 feet, 900 feet, and lastly 1500 feet. The responses range from None (best outcome) to Slight, then Some, then Much, then lastly Unable (worst outcome). The walking distance score was calculated from the 7 questions in the section by way of a weighted sum. A score of 100 indicated no walking impairment. A score of 0 corresponded to the highest degree of walking impairment (NCT00822172)
Timeframe: Baseline, Day 180
| Intervention | score on a scale (Mean) |
|---|---|
| Cilostazol + L-Carnitine | 13.20 |
| Cilostazol + Placebo | 6.57 |
Subjects completed the Walking Impairment Questionnaire (WIQ) whereby they were asked about their maximal walking distance before having to rest as a result of claudication symptoms associated with their peripheral artery disease (PAD). The WIQ was administered at the Baseline, Day 90, and Day 180 visits. On the WIQ subjects were asked a series of questions related to their degree of physical difficulty that best described how hard it was for the subject to walk on level ground without stopping to rest. The questions began by asking the degree of difficulty walking around indoors, then 50 feet, 150 feet, 300 feet, 600 feet, 900 feet, and lastly 1500 feet. The responses range from None (best outcome) to Slight, then Some, then Much, then lastly Unable (worst outcome). The walking distance score was calculated from the 7 questions in the section by way of a weighted sum. A score of 100 indicated no walking impairment. A score of 0 corresponded to the highest degree of walking impairment (NCT00822172)
Timeframe: Baseline, Day 90
| Intervention | score on a scale (Mean) |
|---|---|
| Cilostazol + L-Carnitine | 12.98 |
| Cilostazol + Placebo | 10.01 |
1 review available for carnitine and Peripheral Arterial Diseases
| Article | Year |
|---|---|
Propionyl-L-carnitine for intermittent claudication.
Topics: Ankle Brachial Index; Carnitine; Humans; Intermittent Claudication; Peripheral Arterial Disease; Ran | 2021 |
3 trials available for carnitine and Peripheral Arterial Diseases
| Article | Year |
|---|---|
A study on the efficacy and safety assessment of propionyl-L-carnitine tablets in treatment of intermittent claudication.
Topics: Administration, Oral; Aged; Carnitine; Double-Blind Method; Humans; Intermittent Claudication; Middl | 2013 |
L-Carnitine plus cilostazol versus cilostazol alone for the treatment of claudication in patients with peripheral artery disease: a multicenter, randomized, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Carnitine; Cilostazol; Double-Blind Method; Drug Therapy, Combination; Exercise Test; F | 2012 |
Propionyl-L-carnitine improves endothelial function, microcirculation and pain management in critical limb ischemia.
Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Blood Gas Monitoring, Transcutaneo | 2012 |
4 other studies available for carnitine and Peripheral Arterial Diseases
| Article | Year |
|---|---|
Association of Low Serum l-Carnitine Levels with Peripheral Arterial Stiffness in Patients Who Undergo Kidney Transplantation.
Topics: Adult; Ankle Brachial Index; Biomarkers; Carnitine; Cross-Sectional Studies; Down-Regulation; Female | 2019 |
Daily non-soy legume consumption reverses vascular impairment due to peripheral artery disease.
Topics: Aged; Aged, 80 and over; Ankle Brachial Index; Atherosclerosis; Biomarkers; Carnitine; Carotid Steno | 2013 |
Combination of Cilostazol and L-Carnitine Improves Walking Performance in Peripheral Arterial Disease Model Rats.
Topics: Angiogenic Proteins; Animals; Carnitine; Cilostazol; Disease Models, Animal; Drug Therapy, Combinati | 2015 |
Rehabilitative treatment in peripheral artery disease: protocol application and follow-up.
Topics: Aged; Cardiotonic Agents; Carnitine; Clinical Protocols; Combined Modality Therapy; Diabetes Mellitu | 2010 |